M&A - Inhibikase Therapeutics, Inc.
Form Type: 8-K
Filing Date: 2025-02-24
Corporate Action: Merger
Type: New
Accession Number: 000119312525032821
Filing Summary: On February 21, 2025, Inhibikase Therapeutics, Inc. entered into a Merger Agreement with Project IKT Merger Sub, Inc. and CorHepta Pharmaceuticals, Inc. Merger Sub merged into CorHepta, with CorHepta becoming a wholly-owned subsidiary. The transaction involved payment of $15 million, composed of 4,979,101 shares of common stock as consideration, with 3,319,397 shares awarded as upfront payment. A portion of the upfront shares is held in escrow for potential indemnity obligations. The remaining shares are contingent upon a milestone. On the same date, Chris Cabell was appointed as President leading new developments while the Board expanded and appointed Vincent Aurentz. The report also discusses the employment agreement with Dr. Cabell, outlining salary, compensation, and terms for termination. A press release dated February 24, 2025, announced these developments to the public, highlighting the expansion of the leadership team.
Document Link: View Document
Additional details:
Item 1: Agreement and Plan of Merger
Item 2: CorHepta Pharmaceuticals, Inc.
Item 3: Consideration of $15 million
Item 4: 4,979,101 shares of common stock
Item 5: Appointment of Chris Cabell
Item 6: Appointment of Vincent Aurentz
Item 7: Employment Agreement with Chris Cabell
Item 8: Press release issued on February 24, 2025
Comments
No comments yet. Be the first to comment!